{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:44:05Z","timestamp":1793306645632,"version":"4.5.0"},"reference-count":48,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ulcerative colitis (UC) in pediatric patients often results in corticosteroid (CS) dependency, with many individuals developing resistance to conventional treatments such as anti-TNF agents. Vedolizumab, a monoclonal antibody targeting \u03b14\u03b27 integrin, has shown promise in adult populations, but data on its efficacy and safety in children and adolescents are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This systematic review aims to assess the effectiveness and safety of vedolizumab in treating UC in pediatric patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, data sources, and methods:<\/jats:title>\n                    <jats:p>The PRISMA statement\u2019s guidelines were followed in conducting this systematic review. Up until December 2024, a thorough search was carried out using keywords associated with inflammatory bowel disease (IBD), vedolizumab, and pediatric populations in the Cochrane Library, EMBASE, and PubMed. Case series of children and adolescents (less than 18\u2009years old) with UC or unclassified IBD who were treated with vedolizumab were included in the research. Data on clinical response, mucosal healing, corticosteroid-free remission, clinical remission, and adverse events were extracted. Descriptive statistics were used in the statistical analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 14 papers were considered in the current evaluation of the effectiveness and safety of vedolizumab. Nearly one-third (36%) of patients with UC\/IBD-U experienced clinical remission at 6\u2009weeks, half of the patients at 14\u2009weeks (50%), and 48% and 53% of patients at 22\u2009weeks, respectively. Forty-five percent of patients maintained clinical remission after 1\u2009year. Less than 8% of UC\/IBD-U patients experienced serious side effects, while 15%\u201334% of patients experienced mucosal healing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Vedolizumab exhibits promising efficacy and a favorable safety profile in treating pediatric UC, with a sizable portion of patients achieving both clinical and corticosteroid-free remission. However, due to the limited sample sizes and lack of investigations, more randomized controlled trials and long-term research are needed to confirm these findings and develop more reliable clinical guidelines for its use in children and adolescents with UC. This means that even if the initial findings are promising, additional and better testing is required to ensure that vedolizumab is both effective and safe for young patients with UC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>The PROSPERO registration number for this systematic review is CRD420250651513.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562848251356063","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T07:26:53Z","timestamp":1753255613000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["A systematic review of vedolizumab in treating pediatric ulcerative colitis: efficacy and safety insights"],"prefix":"10.1177","volume":"18","author":[{"given":"Khawla","family":"Abu Hammour","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Biopharmaceutics, Faculty of Pharmacy, University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Abu Hamour","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Jordan University Hospital, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faris","family":"El-Dahiyat","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3325-1442","authenticated-orcid":false,"given":"Mohammed","family":"Zawiah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Clinical Pharmacy, Hodeidah University, Hodeidah, Yemen"},{"name":"Department of Clinical Practice, Faculty of Pharmacy, Northern Border University, Rafha, 76413, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana K.","family":"Abu-Farha","sequence":"additional","affiliation":[{"name":"Rana K. Abu-Farha Department of Clinical Pharmacy and Therapeutics Department, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000660"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04857.x"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-022-03229-x"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.07.011"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.63"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04612.x"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000202"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300904"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy060"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.05.008"},{"key":"e_1_3_4_14_2","unstructured":"EMA. Entyvio. Summary of product characteristics. European Medicines Agency 2024."},{"key":"e_1_3_4_15_2","unstructured":"FDA. ENTYVIO (Vedolizumab) for injection for intravenous use. Food and Drug Administration 2022."},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318484"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw168"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx009"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002035"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa161"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317987"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000865"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000918"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx082"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-018-0868-x"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-020-00396-1"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002556"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa277"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132997"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-021-04063-6"},{"key":"e_1_3_4_31_2","article-title":"Vedolizumab experience in children and adolescents with inflammatory bowel disease: a multicenter observational study","volume":"3","author":"Hajjat TM","year":"2021","unstructured":"Hajjat TM, Mosha M, Whaley KG, et al. Vedolizumab experience in children and adolescents with inflammatory bowel disease: a multicenter observational study. Crohns Colitis 360 2021; 3: otab039.","journal-title":"Crohns Colitis 360"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.06.004"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac036"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16246"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00307-7"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14919"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1699529"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12748"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307008"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.sempedsurg.2017.10.005"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1480-0"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820936536"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050640620948802"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000979"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.08.044"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14930"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050640620965106"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311079"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14075"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251356063","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848251356063","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251356063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T08:19:22Z","timestamp":1767687562000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848251356063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":48,"alternative-id":["10.1177\/17562848251356063"],"URL":"https:\/\/doi.org\/10.1177\/17562848251356063","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"17562848251356063"}}